蛋白激酶B
内科学
内分泌学
蛋白激酶A
生物
肌肉肥大
心肌细胞
磷化氢
磷酸化
心肌细胞
细胞生物学
压力过载
蛋白磷酸酶1
蛋白质降解
激酶
磷酸酶
医学
心肌肥大
作者
Yingyu Bai,Xiaoying Zhang,Ying Liu,Fei Qi,Chong Liu,Xinghao Ai,Mingxin Tang,Christopher Szeto,Erhe Gao,Hua Xiang,Mingxing Xie,Xuejun Wang,Ying Tian,Yongjie Chen,Guowei Huang,Junping Zhang,Weidong Xiao,Lili Zhang,Xueyuan Liu,Qing Yang,Steven R. Houser,Xiongwen Chen
出处
期刊:Circulation Research
[Ovid Technologies (Wolters Kluwer)]
日期:2024-02-16
卷期号:134 (4): 393-410
被引量:1
标识
DOI:10.1161/circresaha.123.322729
摘要
The sympathoadrenergic system and its major effector PKA (protein kinase A) are activated to maintain cardiac output coping with physiological or pathological stressors. If and how PKA plays a role in physiological cardiac hypertrophy (CH) and pathological CH (PaCH) are not clear.Transgenic mouse models expressing a PKA inhibition peptide-GFP fusion protein in a cardiac-specific and inducible manner (cPKAi) were used to determine the roles of PKA in physiological CH during postnatal growth or induced by swimming, and in PaCH induced by transaortic constriction (TAC) or augmented Ca2+ influx. Kinase profiling was used to determine cPKAi specificity. Echocardiography was used to determine cardiac morphology and function. Western blotting and immunostaining were used to measure protein abundance and phosphorylation. Protein synthesis was assessed by puromycin incorporation and protein degradation by measuring protein ubiquitination and proteasome activity. Neonatal rat cardiomyocytes (NRCMs) infected with AdGFP or AdPKAi-GFP were used to determine the effects and mechanisms of cPKAi on myocyte hypertrophy. rAAV9.PKA inhibition peptide-GFP was used to treat TAC mice.(1) cPKAi delayed postnatal cardiac growth and blunted exercise-induced physiological CH; (2) PKA was activated in hearts after TAC due to activated sympathoadrenergic system, the loss of endogenous PKIα (PKA inhibitory peptide α), and the stimulation by noncanonical PKA activators; (3) cPKAi ameliorated PaCH induced by TAC and increased Ca2+ influxes and blunted neonatal rat cardiomyocyte hypertrophy by isoproterenol and phenylephrine; (4) cPKAi prevented TAC-induced protein synthesis by inhibiting mTOR signaling through reducing Akt activity, but enhancing inhibitory GSK-3α and GSK-3β signals; (5) cPKAi reduced protein degradation by the ubiquitin-proteasome system via decreasing RPN6 phosphorylation; (6) cPKAi increased the expression of antihypertrophic ANP; (7) cPKAi ameliorated established PaCH and improved animal survival.Cardiomyocyte PKA is a master regulator of physiological CH and PaCH through regulating protein synthesis and degradation. cPKAi can be a novel approach to treat PaCH.
科研通智能强力驱动
Strongly Powered by AbleSci AI